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Summary
QUESTIONS UNDER STUDY: The prevalence of chronic
kidney disease (CKD) is increasing worldwide, corres-
ponding to an increased risk of cardiovascular disease. The
latest study on prevalence of CKD involving the three lin-
guistic regions of Switzerland dates back to 2002–2003 and
definitions have changed since then. We aimed to assess the
current prevalence and determinants of CKD in the Swiss
general population.
METHODS: We analysed the data of 1353 participants
from a cross-sectional population-based survey performed
in 2010–2012 in the three linguistic regions of Switzerland.
The prevalence of CKD and the derived cardiovascular risk
categories were assessed according to the Kidney Disease –
Improving Global Outcomes (KDIGO) 2012 classification,
using estimated glomerular filtration rate (GFR; CKD-
Epidemiological Collaboration equation) and albuminuria
level. Multivariate logistic regression was used to analyse
factors associated with CKD.
RESULTS: We included 660 men and 693 women, equally
distributed in four age categories (15–29, 30–44, 45–59
and over 60 years). The overall prevalence of CKD was
10.4%. The prevalence in the low, moderate, high and very
high risk KDIGO categories were 89.6%, 8.4%, 1.6% and
0.5%, respectively. The prevalence of CKD was similar
in all linguistic regions. In multivariate analysis, female
gender, older age, diabetes and uric acid were independ-
ently associated with CKD in persons ≥45 y. In younger
participants, diabetes and lower educational level were as-
sociated with CKD.
CONCLUSIONS: In the general Swiss population, CKD
affects one in ten adults. Subjects older than 60 years, as
well as patients with diabetes and hypertension, show a
high prevalence of CKD. Systematic screening may be re-
commended in this population.
Key words: chronic kidney disease; KDIGO 2012
classification; CKD-EPI equation; albuminuria;
Switzerland
Introduction
The prevalence of chronic kidney disease (CKD) is in-
creasing worldwide, amounting to an epidemic outbreak,
which parallels the population aging and the increasing
prevalence of hypertension, diabetes and obesity [1]. CKD
is clearly associated with an increased risk of cardiovascu-
lar morbidity and mortality. Indeed, CKD patients are more
likely to die from a cardiovascular event than to have de-
teriorating kidney function and start dialysis [2].
To better account for the prognostic impact of CKD stages
in term of cardiovascular and renal prognosis, a revised
CKD staging system was proposed by the Kidney Disease
–Improving Global Outcomes (KDIGO) group [3]. In fact,
the previous Kidney Disease Outcomes Quality Initiative
(KDOQI) CKD classification guidelines (2002) [4] have
been questioned, in particular with regard to their tendency
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to overestimate CKD prevalence and fail to predict ac-
curately prognosis and risk [5–7]. According to KDOQI
(2002), CKD is defined, from a two-dimensional al-
gorithm, as either kidney damage (identified by albumin-
uria in the presence of an albumin-to-creatinine ratio
[ACR] >30 mg/g) with or without impaired estimated
glomerular filtration rate (eGFR), or impaired eGFR <60
ml/min/1.73 m2. Based on a collaborative meta-analysis
confirming the independent and combined associations of
eGFR and albuminuria as predictors for all-cause mortality,
cardiovascular mortality, acute kidney injury, progressive
CKD and end-stage renal disease (ESRD) [8], the CKD sta-
ging system was revised, incorporating the severity of al-
buminuria at all stages of CKD in a risk prediction instru-
ment, as reported by the KDIGO (2012) CKD guidelines
[3].
The new KDIGO (2012) classification was recently used
to explore the prevalence of CKD in the CoLaus cohort,
a Swiss population-based study performed in a single city,
Lausanne [9]. However, the latest study focusing on CKD
prevalence and its determinants in the three Swiss linguist-
ic regions dates back to 2003 [10], relied on the KDOQI
(2002) classification and used the Modification of Diet
in Renal Disease (MDRD) instead of the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) equation.
The aims of this study were (i) to estimate the prevalence
of CKD in the Swiss adult population according to KDIGO
(2012) classification, exploring the presence of regional
differences, (ii) to analyse the CKD-associated cardiovas-
cular risk, and (iii) to identify factors associated with CKD
in the Swiss adult population that could guide targeted
screening for CKD.
Methods
Sampling strategy
This analysis was based on the data of the cross-sectional,
population-based Swiss Survey on Salt (SSS) [11], pro-
moted by the Swiss Federal Office of Public Health (Bun-
desamt für Gesundheit; BAG) with the primary aim to es-
timate dietary salt intake and hypertension prevalence. The
final study population included a population-based sample
covering nine cantons: Basel, Fribourg, Geneva, Luzern,
St-Gallen, Ticino, Vaud, Valais and Zürich, reflecting the
geographical and cultural diversity of permanent residents
in Switzerland aged ≥15 years.
Recruitment took place from January 2010 to March 2012
and was based on a two-level sampling strategy. House-
holds were randomly selected by the Swiss Federal Statist-
ical Office, based on the Swiss fixed-line phone directory,
which includes all landline phone connections in Switzer-
land and is regularly updated by the major Swiss phone
provider. In a first step, we contacted these households
by sending an information letter, followed by phone calls
with a maximum of three attempts on different days. In a
second step, we randomly selected, during the phone call,
one person from the household to take part in the study,
using a computer-generated random number. The sample
population was selected to represent the three linguistic re-
gions of Switzerland (French, German and Italian) and to
be equally distributed in four age categories (15–30, 30–45,
45–60 and over 60 years) for each gender. The study in-
cluded 1515 participants in total. The overall participation
rate of SSS was 10%, without differences between linguist-
ic regions. Limited convenience sampling was necessary
to overcome recruitment difficulties in young and middle-
aged people. Details of the SSS study design have been
published previously [12].
Only subjects with complete data allowing kidney function
assessment were considered for the present analysis. Parti-
cipants with an incomplete urine collection (defined as re-
ported incomplete collection, urinary volume <300 ml and/
or collection time <20 h) or suspected urine overcollection
(identified as 24-hour urinary creatinine >43 mg/mmol/kg,
corresponding to the extreme outliers), were excluded from
the analysis.
Ethics
The SSS complied with the Declaration of Helsinki and
was approved by the local Institutional Ethics Committees
of each participating centre. All participants gave written
informed consent. For participants below age 18 years,
written consent from one parent or a legal representative
was obtained.
Clinical data
The study participants attended the study centre on two
occasions: one baseline visit and one follow-up visit the
following day, after completion of the 24-hour urine col-
lection. Body mass index (BMI) was calculated as weight
divided by height in meter squared and categorised in three
groups according to World Health Organization recom-
mendations: lean (<25 kg/m2), overweight (≥25 to <30
kg/m2) and obese (≥30 kg/m2). Blood pressure was meas-
ured five times at each visit on the left arm after at least 5
minutes rest in the seated position using a clinically valid-
ated automated oscillometric device (Omron® HEM-907,
Matsusaka, Japan). The mean of the ten blood pressure
readings was used for analyses. Hypertension was defined
as mean systolic blood pressure ≥140 mm Hg or mean dia-
stolic blood pressure ≥90 mm Hg or antihypertensive med-
ication. Diabetes mellitus was considered as present in par-
ticipants taking antidiabetic drug treatment.
Data on medication, smoking status, education level, phys-
ical activity and dietary habits were collected in a question-
naire. The term ‘smokers’ was used for current smokers.
Alcohol consumption was split into three categories (<1
unit in the last week, >1 unit/week but <1 unit/day, ≥1
unit/day). Education was split into three levels (primary,
secondary, tertiary). Physical activity was considered as
present if participants reported practising sport more than
once a week. Linguistic regions were classified into three
categories: French, German and Italian.
Participants were given two 3-litre plastic bottles and re-
ceived standardised instructions on how to make a 24-hour
urine collection. An optional nonfasting blood sample was
collected.
Laboratory analysis
Urine and blood samples were sent to the Central Chemical
Laboratory of Lausanne University Hospital (CHUV,
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Lausanne, Switzerland) for centralised analyses with stand-
ard methods. Serum and urine creatinine were measured
using the Jaffé kinetic compensated method (Roche Dia-
gnostics, Switzerland). Plasma uric acid was measured by
means of enzymatic colorimetry (Uricase-PAP, Roche Dia-
gnostics, Switzerland). Urine albumin was assessed with
immunonephelometry.
Chronic kidney disease definition
Kidney function was calculated with the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) equation
[13]. The CKD stages were defined according to the re-
vised KDIGO (2012) classification, which includes five
stages of eGFR (G1 to G5) and three levels of albuminuria
based on the albumin-to-creatinine ratio, ACR (A1 <30
mg/g; A2 30–300 mg/g; A3 >300 mg/g) [3]. According to
the guidelines, either ACR or the absolute value of 24-hour
urinary albumin excretion can be used for CKD classific-
ation. The two measurements were strongly correlated in
our population (r = 0.968, p <0.001). The KDIGO (2012)
classification allows further stratification into four categor-
ies with similar relative risk for renal and cardiovascular
outcomes: low, medium, high and very high risk. For ex-
ample, the cardiovascular mortality risk increases 1.5–2.2
fold in the medium-risk category, 2.2–3.7 fold in the high-
risk and 4.1–14.0 fold in the very high-risk category, when
compared with the low-risk population [3]. The term CKD
was used to define the medium- to very high-risk KDIGO
(2012) categories.
Statistical analyses
Statistical analyses were performed using Stata 11.0 (Stata
Corp, College Station, USA).
Mean and standard deviation were used to describe nor-
mally distributed continuous variables, and percentages to
describe dichotomous or categorical variables. Student t-
test, analysis of variance and chi-squared test were per-
formed to compare the characteristics of groups where ap-
propriate. The four predefined age categories of the ori-
ginal study were maintained and a nonparametric test was
used to assess trend across ordered age categories. Sub-
sequently, the older age group was split into two groups,
60–69 years and ≥70 years, to give more detailed informa-
tion about the incidence of CKD in these two age groups.
Linear regression analysis was used to study the associ-
ation between eGFR and age as continuous variables. Lin-
earity of the correlation was confirmed visually by com-
puting a locally weighted least-squares regression and a
residual plot. Logistic regressions were used to explore
the factors associated with CKD, defined as medium- to
very high-risk KDIGO (2012) categories. Tested independ-
ent variables were: linguistic region, age, gender, BMI cat-
egory, hypertension, diabetes, smoking status, educational
status, physical activity and serum uric acid. The factors
having significances of p-values <0.10 were inserted in
a multivariate model using a forward-stepwise procedure
and adding interactions term between the covariates. Since
most of the covariates showed significant interaction with
age (p <0.05), the multivariate analysis was stratified by
age into two strata (15–44 years and 45 years and older)
and the same procedure repeated for each stratum, finding
no significant interaction between covariates.
Results
Of the 1515 participants who completed the SSS survey,
162 (10.7%) were excluded from this analysis as it was
impossible to assess their renal function because of either
blood sampling refusal (n = 132), incomplete urine collec-
tion (n = 28) or missing ACR results (n = 2). Excluded sub-
jects were younger (39.5 ± 18.5 vs 48.6 ± 18.2 y, p <0.001),
had a lower BMI (24.3 ± 4.8 vs 25.3 ± 4.6 kg/m2, p =
0.004) and were more likely to be nonhypertensive (13.4
vs 5.8%, p <0.001) than the analysed population. There
was no difference in gender prevalence. Finally, 1353 par-
ticipants (660 men and 693 women) were included in the
present analysis; their characteristics by gender and age
strata are presented in table 1.
Chronic kidney disease prevalence and risk categories
Table 2 shows the percentages of participants in each cat-
egory of the revised KDIGO (2012) classification for CKD.
The overall prevalence of CKD in the population was
10.4%. The prevalence in the low-, moderate-, high- and
very high-risk categories was 89.6%, 8.4%, 1.6% and
0.5%, respectively. The prevalence of CKD was similar
across linguistic regions (fig. 1), being 9.1% in French-,
10.3% in Italian- and 11.2% in German-speaking Switzer-
land (p = 0.53), with similar distributions across CKD risk
categories (p = 0.43).
Factors associated with chronic kidney disease
Figure 2 represents the prevalence of CKD by gender and
age group. CKD prevalence increased among age categor-
ies, with a steep increase after 60 years. For both genders
combined, the prevalence was 3.1% in participants aged
15–29, 3.7% at 30–44 years, 4.3% at 45–59 years and
25.4% over 60 years (p <0.0001 for trend). Further splitting
the older age category into two groups (60–69 years old, n
= 244 and ≥70 years, n = 174) confirmed the significantly
Figure 1
Prevalence of chronic kidney disease (KDIGO 2012), by gender
and linguistic region. p-value not significant for difference between
genders for each linguistic region (chi squared test); p-value not
significant for difference between linguistic regions (chi squared
test).
KDIGO = Kidney Disease – Improving Global Outcomes
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higher prevalence of CKD in the oldest age group (41.4%)
when compared with the 60–69 year group (13.9%, p
<0.001). When considering the overall prevalence, there
were no significant gender differences, with a prevalence
of 10.3% in men and 10.5% in women (p = 0.89). Pre-
valence between genders was similar in people aged ≥60
years: 26.9% and 23.6% in men and women, respectively,
(p = 0.48). However, CKD was significantly more preval-
ent in younger women than men (aged 15–59 years): 1.6%
vs 5.6% (p = 0.001). The unadjusted eGFR evolution with
age was characterised by a linear decline, with a similar
slope in both genders: –0.79 (0.03) ml/min/1.73 m2/y for
men and –0.80 (0.03) ml/min/1.73 m2/y for women (fig. 3).
The unadjusted prevalence of CKD was significantly high-
er in hypertensive patients (5.7% vs 22.7%, p <0.0001) and
diabetic subjects (9.5% vs 37.8%, p <0.0001) compared to
participants without these conditions (fig. 4). We observed
no significant trend in the prevalence of CKD across BMI
Figure 2
Prevalence of chronic kidney disease (KDIGO 2012), by gender
and age category. p-values are from a nonparametric test for trend,
comparing the trend in combined medium- to very high-risk
categories vs low-risk category across age groups
KDIGO = Kidney Disease – Improving Global Outcomes
categories: 9.2% in normal weight people, 12.1% in over-
weight people and 11.1% in obese people (p for trend =
0.181) (fig. 4). Results were similar in both genders.
In the multivariate analysis (table 3), female gender, older
age, diabetes and uric acid were independently associated
with a higher prevalence of CKD in subjects aged 45 years
and older. In younger participants, only diabetes and a
lower educational level were independent determinants of
CKD.
Discussion
We report the first data about the prevalence of CKD in the
three linguistic regions of Switzerland, defined on the basis
of both eGFR, calculated with the CKD-EPI formula, and
albuminuria, according to the new KDIGO (2012) classi-
fication, in a population-based sample. We found CKD to
Figure 3
Relationship between renal function (eGFR by CKD-EPI equation)
and age in the Swiss population.
Bold lines represent the unadjusted linear regression estimation,
gray lines 95% confidence interval. Decline slope (SE): –0.79 (0.03)
ml/min/1.73 m2/year for men, –0.80 (0.03) ml/min/1.73 m2/year for
women
CKD-EPI = Chronic Kidney Disease Epidemiological Collaboration
Table 1: Participants’ characteristics, by gender and age strata.
Men Women
Age group (y) 15–29 30–44 45–59 ≥60 15–29 30–44 45–59 ≥60
No. 135 127 171 227 155 169 178 191
Age (years) 23.4 (4.1) 38.6 (4.5) 52.5 (4.3) 69.8 (7.1)a 23.5 (4.1) 38.1 (4.1) 52.7 (4.2) 70.1 (7.0)a
Nationality (% Swiss) 80 71.6 77.2 81.1 85.2 75.1 75.3 83.2
Education (%)
Primary 28.9 6.30 10.0 14.2a 13.5 8.3 17.5 28.0a
Secondary 40.0 22.8 37.6 48.7a 52.3 41.7 50.9 48.2a
Tertiary 31.1 70.9 52.4 37.2a 34.2 50.0 31.6 23.8a
Current smoking (%) 11.3 24.4 41.0 46.7a 14.8 24.3 32.6 24.6b
BMI (kg/m2) 23.1 (3.4) 25.8 (3.7) 27.3 (4.1) 27.2 (4.0)c 22.6 (4.3) 23.9 (4.3) 25.3 (5.1) 26.0 (5.1)c
Hypertension (%) 3.7 13.4 39.2 66.1a 1.9 3.0 15.7 51.8a
Diabetes (%) 0 1.6 2.3 11.0 0 0.6 2.2 4.7
Plasma creatinine (µmol/l) 85.1 (9.8) 88.2 (12.4) 86.7 (11.8) 95.3 (29.0)c 68.9 (8.7) 68.0 (10.4) 71.5 (11.1) 75.4 (14.6)c
eGFR CKD-EPI (ml/min/1.73 m2) 110.7 (12.9) 95.8 (13.3) 88.4 (11.7) 73.4 (16.2)c 108.0 (14.3) 98.4 (13.9) 84.9 (13.6) 71.9 (14.7)c
Albuminuria (mg/24 h) 6.9 (8.1) 7.1 (22.5) 7.1 (9.9) 25.4 (127.1)d 9.1 (17.7) 14.2 (55.3) 6.9 (10.0) 8.6 (13.3)
BMI = body mass index; CKD-EPI = Chronic Kidney Disease Epidemiology Collaboration; eGFR = estimated glomerular filtration rate
Data are mean (standard deviation) unless otherwise specified.
a p <0.001 between age groups, by gender (chi-squared test)
b p <0.05 between age groups, by gender (chi-squared test)
c p <0.001 between age groups, by gender (ANOVA)
d p <0.05 between age groups, by gender (ANOVA)
Original article Swiss Med Wkly. 2016;146:w14313
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 4 of 12
be present in one in ten Swiss adults and one in four parti-
cipants over 60 years of age. These data match with simil-
ar population-based studies from other countries, combin-
ing eGFR and albuminuria to define CKD, which reported
a CKD prevalence of between 8% and 13.2% [6, 14–19].
The three linguistic/geographic regions of Switzerland
presented similar results. The global prevalence of CKD
was similarly distributed across the genders in older
people, but among those younger than 60 years CKD was
more frequent in women than men. However, in an age-
stratified, adjusted analysis, we found several differences
in the determinants of CKD between younger and older
participants. Diabetes was the only factor associated with
a higher prevalence of CKD in both age strata, despite a
greater risk increase in younger than in older subjects. In
several previous cross-sectional and longitudinal analyses,
older age, female gender and higher serum uric acid were
independently associated with CKD prevalence [9, 20–25].
In our population, these factors were also independently as-
sociated with CKD in participants aged over 45 years, but
not in younger ones. Interestingly, a lower educational level
was associated with a higher prevalence of CKD in young-
er participants. This factor has also been associated with
kidney outcomes in the CoLaus population [26]. In contrast
to some previous reports, we found neither a difference in
CKD prevalence between lean, overweight and obese parti-
cipants, nor an association between hypertension and CKD
prevalence [9, 27, 28].
In Europe there appears to be a south-north gradient in
CKD prevalence: the prevalence of CKD is higher in
Southern countries (12.7–13.2%) [29, 30] than in the
Northern countries (8–10.2%) [31, 32]. In contrast with
these observations, we found no differences between lin-
guistic regions in our analysis.
Table 2: Distribution of the chronic kidney disease risk categories according to KDIGO (2012).
Albuminuria stages
A1 A2 A3 Total
Normal to mildly
increased
Moderately increased Severely increased
<30 mg/g
<3 mg/mmol
30–300
3–30 mg/mmol
>300 mg/g
>30 mg/mmol
G1 Normal or high ≥90 48.04 1.85 0.07 49.96
G2 Mildly decreased 60–89 41.54 1.26 0 42.79
G3a Mild-moderate 45–59 5.25 0.30 0.07 5.62
G3b Moderate-Severe 30–44 1.18 0.22 0 1.40
G4 Severe 15–29 0.07 0.07 0.07 0.22
G5 Kidney failure <15 0 0 0 0
GFR
(ml/min/1.73 m2)
CKD-EPI equation
Total 96.08 3.70 0.22 100
CKD = chronic kidney disease; CKD-EPI = Chronic Kidney Disease Epidemiology Collaboration; GFR = glomerular filtration rate; KDIGO = Kidney Disease – Improving
Global Outcomes
Colours correspond to categories with similar relative risk for renal and cardiovascular outcomes [3]: low risk (light grey, 89.6%): reference category (relative risk, RR = 1);
moderately increased risk (medium grey, 8.4%): RR for cardiovascular mortality 1.5–2.2; RR for progressive CKD 1.9–3.3; high risk (dark grey, 1.6%): RR for
cardiovascular mortality 2.2–3.7; RR for progressive CKD 4.0–8.1; very high risk (black, 0.5%): RR for cardiovascular mortality 4.1–14.0; RR for progressive CKD 9.4–57.0
Table 3: Factors associated with chronic kidney disease in univariate and multivariate logistic regression stratified by age.
Univariate Multivariate
age 15–44 (n = 586)
Multivariate
age ≥45 (n = 767)
Covariable Odds ratio
(95% CI)
p-value Odds ratio
(95% CI)
p-value Odds ratio
(95% CI)
p-value
Gender
(women vs men)
1.03 (0.72–1.45) 0.890 3.44 (0.76–15.67) 0.110 1.88 (1.13–3.14) 0.016
Age
(per 1 year increase)
1.07 (1.06–1.09) <0.001 1.00 (0.94–1.06) 0.928 1.11 (1.08–1.14) <0.001
Diabetes
(absent = Ref.)
5.80 (3.09–10.89) <0.001 44.23 (1.76–1115) 0.021 2.75 (1.30–5.81) 0.008
Hypertension
(absent = Ref.)
4.85 (3.37–6.96) <0.001 1.90 (0.18–20.07) 0.593 1.18 (0.71–1.95) 0.520
Serum uric acid (mmol/l) 1.006 (1.00–1.01) <0.001 0.992 (0.983–1.001) 0.094 1.008 (1.005–1.011) <0.001
Education level
Primary
Secondary
Tertiary
1.0 (Ref.)
0.57 (0.36–0.90)
0.49 (0.30–0.78)
0.015
0.003
1.0 (Ref.)
0.09 (0.02–0.39)
0.32 (0.11–1.00)
0.001
0.051
1.0 (Ref.)
1.04 (0.58–1.88)
0.76 (0.40–1.44)
0.891
0.397
Body mass index
<25 kg/m2
25–30 kg/m2
>30 kg/m2
1.0 (Ref.)
1.36 (0.93–2.00)
1.24 (0.74–2.07)
0.111
0.412
– –
Current smoking (absent = Ref.) 1.22 (0.84–1.78) 0.304 – –
Physical activity (absent = Ref.) 1.02 (0.72–1.46) 0.904 – –
Language region
French
German
Italian
1.0 (Ref.)
1.26 (0.84–1.89)
1.15 (0.66–2.02)
0.261
0.617
– –
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Direct comparisons between our results and previous
population-based analyses performed in Switzerland are
complicated by differences in population sampling, age re-
striction and definition of CKD. The prevalence of CKD
we found is in line with the results of the CoLaus cohort
[9], based on a single Swiss city, Lausanne, and using the
same definitions. The Swiss SAPALDIA study [10] repor-
ted a CKD prevalence of 1.1% in men and 7.9% in wo-
men aged below 55 years, 7.1% in men and 23.5% in wo-
men between 55 and 65 years, 12.9% in men and 35.9%
in women over 65 years. However, in this study CKD was
defined using the MDRD formula, with an eGFR cut-off
<60 ml/min/1.73 m2, and albuminuria was not measured.
Growing evidence supports the use of eGFR and urinary
spot albumin in the assessment of CKD prevalence in epi-
demiological and clinical works, both being strong inde-
pendent risk factors for increased mortality, cardiovascular
events, acute kidney injury [8, 33, 34], and venous throm-
boembolism [35]. Unfortunately, these tests have signific-
ant limitations. Urinary albumin-to-creatinine ratio correl-
ates closely with 24-hour urinary albumin excretion, but
mild albuminuria may be transiently present in the absence
of kidney pathology, for example by fever or after exercise.
Longitudinal studies have shown that albuminuria may re-
gress in people with nondiabetic [36] and diabetic CKD
[37]. The equation used to estimate GFR also plays an im-
portant role, especially in subjects with early CKD. Sever-
al Swiss laboratories automatically still report the MDRD
[38] equation-based eGFR whenever a serum creatinine is
requested. The MDRD equation was developed in people
with CKD and has been shown to systematically under-
estimate GFR above the threshold of 60 ml/min/1.73 m2
[39], leading to an overestimation of CKD prevalence in
healthy subjects. The CKD-EPI equation [13] has proven
to be more accurate than MDRD in patients with eGFR ≥60
mL/min/1.73 m2 and [40] and to predict all cause and cardi-
ovascular mortality, and progression toward end-stage ren-
al disease [41].
The new KDIGO (2012) CKD classification integrates a
cardiovascular risk prediction instrument, based on eGFR
and albuminuria, which allowed us to assess the CKD-as-
sociated cardiovascular risk in the Swiss population: in our
Figure 4
Prevalence of moderate, high and very high risk categories using
the CKD KDIGO(2012) classification, by diabetes (panel a),
hypertension (panel b), and BMI categories (panel c).
CKD = chronic kidney disease; DM = diabetes mellitus; KDIGO =
Kidney Disease – Improving Global Outcomes; HT = arterial
hypertension.
study, 89.6% of the population ranked in the low-risk cat-
egory, 8.4% in the moderate-risk, 1.6% in the high-risk,
and only 0.5% in the very high-risk category. The risk-cat-
egory distribution we found is in line with the results re-
cently reported for the population of the CoLaus cohort [9].
In our population, a higher prevalence of CKD was found
in three subgroups: participants older than 60 years (25%),
diabetic (37%) and hypertensive (23%) subjects. This ob-
servation may warrant systematic screening of asympto-
matic subjects presenting these risk factors for CKD, as
suggested by several international medical societies
[42–44], although the risk of progression towards end-stage
renal disease is very low for the majority of elderly subjects
with CKD stage 2 and 3. Contrariwise, routine screening
for CKD in asymptomatic adults without risk factors for
CKD is not supported by scientific evidence [43, 45].
Our analysis has some limitations. First, as in many other
epidemiological studies in this area, our estimates have
been based on single serum creatinine and urinary albumin
analysis results. According to the guidelines, the definition
of CKD requires the demonstration of reduced kidney
function or kidney damage signs for >3 months and this
time constraint is likely to reduce the CKD prevalence ob-
served in single sample studies. The cross-sectional nature
of the study furthermore limits causal inferences. Some of
the factors (such as serum uric acid) that we observed to
be associated with CKD could either precede or follow the
appearance of CKD. Only a longitudinal trial would cla-
rify the temporal sequence and whether baseline charac-
teristics are associated with incident CKD or vice versa.
For serum and urine creatinine analysis, a compensated
isotope dilution mass spectrometry-traceable Jaffe method
(not enzymatic) was used, similarly to most of the previous
epidemiological studies about CKD prevalence. The small
bias due to the method is minimised by the use of the
appropriate calibrated CKD-EPI equation and centralised
analyses. Because of the limited numbers of participants
belonging to the medium-, high- and very high-risk cat-
egories of the KDIGO (2012) classification, we were ob-
liged to pool the three categories in one group (the CKD
group) to explore correlations. One main limitation of our
study is the low overall participation rate of 10% from
the original randomly selected sample, which could limit
generalisability of the results and could be explained by
the two-stage sampling strategy (the subject we contacted
by phone was not automatically the one selected to enter
the study) and the unattractiveness of 24-hour urine col-
lection. Furthermore, the optional character of the blood
sample may have biased the results of the present analysis
in young and middle-aged population strata, where more
women than men accepted the blood collection.
In conclusion, one in ten adults has CKD in the Swiss
general population, without significant regional differen-
ces. Subjects older than 60 years, as well as diabetic and
hypertensive patients show a higher prevalence of CKD
and systematic screening including creatinine and albumin-
uria measurement may be warranted in these groups of
subjects to prevent hospitalisations and to reduce cardi-
ovascular complications by implementing adequate cardi-
ovascular prevention [46].
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Figures (large format)
Figure 1
Prevalence of chronic kidney disease (KDIGO 2012), by gender and linguistic region. p-value not significant for difference between genders for
each linguistic region (chi squared test); p-value not significant for difference between linguistic regions (chi squared test).
KDIGO = Kidney Disease – Improving Global Outcomes
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Figure 2
Prevalence of chronic kidney disease (KDIGO 2012), by gender and age category. p-values are from a nonparametric test for trend, comparing
the trend in combined medium- to very high-risk categories vs low-risk category across age groups
KDIGO = Kidney Disease – Improving Global Outcomes
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Figure 3
Relationship between renal function (eGFR by CKD-EPI equation) and age in the Swiss population.
Bold lines represent the unadjusted linear regression estimation, gray lines 95% confidence interval. Decline slope (SE): –0.79 (0.03) ml/min/
1.73 m2/year for men, –0.80 (0.03) ml/min/1.73 m2/year for women
CKD-EPI = Chronic Kidney Disease Epidemiological Collaboration
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Figure 4
Prevalence of moderate, high and very high risk categories using the CKD KDIGO(2012) classification, by diabetes (panel a), hypertension
(panel b), and BMI categories (panel c).
CKD = chronic kidney disease; DM = diabetes mellitus; KDIGO = Kidney Disease – Improving Global Outcomes; HT = arterial hypertension.
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